Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Smith & Nephew Snats ( (SNN) ) has shared an announcement.
On August 28, 2025, Smith+Nephew announced the appointment of Dr. Garheng Kong as an independent Non-Executive Director and member of the Audit Committee, effective September 1, 2025. Dr. Kong brings extensive experience in the medtech and biopharma sectors, having held various executive and non-executive roles, which is expected to enhance the company’s strategic direction and innovation capabilities.
The most recent analyst rating on (SNN) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the most significant factors driving the score. The stock’s bullish technical indicators are tempered by overbought signals, and the valuation suggests it may be overvalued. Despite challenges in emerging markets and potential tariff impacts, the company’s strategic initiatives and share buyback plan reflect confidence in sustaining growth.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith+Nephew is a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue. The company operates in three main business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Founded in 1856 in Hull, UK, Smith+Nephew now operates in around 100 countries and reported annual sales of $5.8 billion in 2024. It is a constituent of the FTSE100.
Average Trading Volume: 964,567
Technical Sentiment Signal: Buy
Current Market Cap: $16.24B
For detailed information about SNN stock, go to TipRanks’ Stock Analysis page.